Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating and $6 price target The shares are currently trading below the company’s cash position with three data readouts over the next 12-15 months, the analyst tells investors in a research note. The firm believes each readout offers “meaningful upside” to Aclaris shares. Piper believes the company’s lead program, bosakitug, has demonstrated proof of efficacy activity in a small Phase 2a study in moderate to severe atopic dermatitis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics Highlights Clinical Pipeline and Outlook
- Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
- Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
- Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
- Aclaris Therapeutics Approves 2025 Equity Incentive Plan